Mabley, J.G., Soriano, F.G., Pacher, P., Hasko, G., Marton, A., Wallace, R., Salzman, A.L. and Szabo, C. (2003) The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis European Journal of Pharmacology, 466 (3). pp. 323-329. ISSN 0014-2999Full text not available from this repository.
This study evaluated the effects of the adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA), in two murine models of colitis, the dextran sodium sulphate-induced colitis and the spontaneous colitis found in interleukin-10 gene deficient mice. IB-MECA was given orally twice a day at a dose of either 1 or 3 mg/kg/day. Evaluation of colon damage and inflammation was determined grossly (body weight, rectal bleeding) and biochemically (colon levels of myeloperoxidase, malondialdehyde, chemokines and cytokines). There was significantly increased inflammatory cell infiltration into the colon associated with an increase in colon levels of cytokines and chemokines; with subsequent free radical related damage in both dextran sodium sulphate-induced colitis and 10-week-old interleukin-10−/− mice. IB-MECA protected in both models against the colitis induced inflammatory cell infiltration and damage and attenuated the increases in colon inflammatory cytokine and chemokine levels. Thus activation of the adenosine A3 receptor is effective in protecting against colitis.
|Item Type:||Journal article|
|Uncontrolled Keywords:||Colitis; Adenosine; Cytokine; Chemokine|
|Subjects:||B000 Health Professions > B200 Pharmacology Toxicology and Pharmacy|
|DOI (a stable link to the resource):||10.1016/S0014-2999(03)01570-X|
|Faculties:||Faculty of Science and Engineering > School of Pharmacy and Biomolecular Sciences > Chemical Biology|
|Depositing User:||editor spbs|
|Date Deposited:||21 Nov 2006|
|Last Modified:||15 Apr 2014 14:06|
Actions (login required)
Downloads per month over past year